Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases
  • 18
    May

Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases

  • Posted by:
  • Anagenesis

Illkirch Graffenstaden, France – May 18, 2017 – Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases.
BI-ANAG PR May 18 2017

BI – Anagenesis CP_18 mai 2017